Wednesday 03 July 2024
Internal Reference Number: FOI_7543
Date Request Received: 10/11/2023 00:00:00
Date Request Replied To: 05/12/2023 00:00:00
This response was sent via: By Email
Request Summary: Request on the combination of Gastric Oesophageal cancer and Ovarian cancer.
Request Category: Companies
| Question Number 1: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: •CAPOX (Capecitabine with Oxaliplatin) 0 patients • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 0 patients • Lonsurf (Trifluridine - tipiracil) 0 patients • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 patients • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 patients Any other systemic anti-cancer therapy <5 • Palliative care only - Information not held | |
| Question Number 2: How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with: • Nivolumab monotherapy or combination with Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 2: • Nivolumab monotherapy or combination with Ipilimumab 0 patients • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 patients • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) <5 patients • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) <5 patients • Any other systemic anti-cancer therapy <5 patients • Palliative care only -Information not held | |
| Question Number 3: How many patients were treated in the past 3 months for ovarian cancer (any stage) with: • Paclitaxel in combination with a platinum-based compound • Platinum-based therapy alone (cisplatin or carboplatin) • Bevacizumab in combination with paclitaxel and carboplatin • Olaparib • Olaparib + Bevacizumab • Niraparib • Rucaparib | |
| Answer To Question 3: • Paclitaxel in combination with a platinum-based compound 8 patients • Platinum-based therapy alone (cisplatin or carboplatin) <5 patients • Bevacizumab in combination with paclitaxel and carboplatin < 5 patients • Olaparib <5 patients • Olaparib + Bevacizumab <5 patients • Niraparib <5 patients • Rucaparib < 5 patients | |
| Question Number 4: If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with: • Olaparib • Olaparib + Bevacizumab • Niraparib • Other treatments | |
| Answer To Question 4: • Olaparib <5 patients • Olaparib + Bevacizumab <5 patients • Niraparib 0 • Other treatments - Information not held. | |
| Question Number 5: Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part. | |
| Answer To Question 5: none | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
